Document is current
Any future updates will be listed below
-
Authors
Miaris, Nikolaos https://orcid.org/0000-0002-3917-0918
Rajabali, Husein
Quaife, Nicholas M https://orcid.org/0000-0003-2755-2086
Riesgo Gil, Fernando https://orcid.org/0000-0002-3094-0867
Dar, Owais https://orcid.org/0000-0002-7557-8769
Morley-Smith, Andrew https://orcid.org/0000-0003-3005-6382
Robertus, Jan Lukas
Usman, Muhammad
Pantazis, Antonis
Banerjee, Rajasi
Segulin, Barbara https://orcid.org/0009-0002-2016-9519
Luescher, Thomas https://orcid.org/0000-0002-5259-538X
Bucciarelli-Ducci, Chiara https://orcid.org/0000-0002-2515-0852
Chow, Kelvin
Kellman, Peter https://orcid.org/0000-0002-9875-6070
Wong, Joyce
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 21 November 2025
First Online: 12 December 2025
Declarations
:
: Outside this work, Thomas Luescher declares research and educational grants to the institution from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Menarini Foundation, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, and Vifor and honoraria from Amgen, Dacadoo, Daiichi Sankyo, Menarini Foundation, Novartis, Novo Nordisk, Philips, and Pfizer. He holds leadership positions at the European Society of Cardiology, Swiss Heart Foundation, and the Foundation for Cardiovascular Research—Zurich Heart House. Chiara Bucciarelli-Ducci is the CEO (part-time) of the Society for Cardiovascular Magnetic Resonance and received consultancy fees from Bayer, and speaker fees from Siemens Healthineers, GE HealthCare, Bayer, Philips, and Circle Cardiovascular Imaging. Kelvin Chow reports a relationship with Cardiovascular MR R&D, Siemens Healthcare Ltd., Calgary, Alberta, Canada that includes employment. Other authors have nothing to disclose.
